After nearly tripling the company’s value, CEO Lars Fruergaard Jørgensen is preparing to exit amid boardroom shifts. Novo ...

and Novo Nordisk revealed new data pointing to a “clinically meaningful” improvement in osteoarthritis patients’ pain and physical function in the STEP 9 trial.

Much has been learned about GLP-1s over many years, but little is understood about why the degree of response to them varies ...

Novo Nordisk is set to release results on May ... Sales of its other products, osteoarthritis knee pain drug, Zilretta and iovera medical device are expected to have increased in the to-be ...

Eli Lilly has become the leader in new prescriptions and is gaining market share in the incretins analogues market against Novo Nordisk (see image below). Mounjaro/Zepbound’s sales performance ...

WLMs included several drugs given FDA approval for short-term and long-term use, like semaglutide 2.4 mg (Wegovy, Novo Nordisk), liraglutide ... sleep apnea, osteoarthritis, steatotic liver ...

Medscape News UK, April 29, 2025 OARSI 2025 Osteoarthritis Linked to Other ... Medscape Medical News, April 28, 2025 Novo Nordisk's Obesity Drug Wegovy Debuts in Thailand Novo Nordisk has launched ...

Medscape Medical News, April 28, 2025 OARSI 2025 Encouraging Results Seen in Metformin Trial for Knee OA A 6-month study found moderate reductions in knee osteoarthritis pain in patients with ...

While still early, the data suggests a stronger weight-reducing effect than Novo Nordisk’s GLP-1 agonist ... obstructive sleep apnoea, and knee osteoarthritis. “We believe that combining ...

Teal Health's test would give an alternative to in-office pap smears. Other pharma and health industry news covers a new CEO at the American Medical Association; robots at Walgreens; a startup from ...